Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission.

[en] BACKGROUND: We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukemia (sAML). METHODS: Inclusion criteria consisted of >/= 18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT. RESULTS: One hundred forty six patients met the study inclusion criteria. Status at transplantation was first CR (n=97), primary refractory sAML (n=30) or relapsed (n=19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17%) failed to engraft. This include 13% of patients transplanted in first CR versus 30% of those transplanted with active disease (P=0.008)). Two-year incidences of relapse were 25% in first CR patients versus 36% in those with advanced disease (P=0.06) while 2-year incidences of nonrelapse mortality were 35% and 49% (P=0.03), respectively. At 2-year overall survival, leukemia-free survival and graft-versus-host disease (GVHD)-free relapse free survival were 42% versus 19% (P<0.001), 40% versus 16% (P<0.001), and 26% versus 12% (P=0.002) in first CR patients versus those with advanced disease, respectively. CONCLUSIONS: We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40% of patients with sAML in first CR. This article is protected by copyright. All rights reserved.

Disciplines :

Hematology

Author, co-author :

Baron, Frédéric ; Université de Liège - ULiège > Hematology

Labopin, Myriam

Ruggeri, Annalisa

Volt, Fernanda

Mohty, Mohamad

Blaise, Didier

Chevallier, Patrice

Sanz, Jaime

Fegueux, Nathalie

Cornelissen, Jan J.

More authors (4 more)

Language :

English

Title :

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission.

Publication date :

2019

Journal title :

Journal of Internal Medicine

ISSN :

0954-6820

eISSN :

1365-2796

Publisher :

Blackwell, Oxford, United Kingdom

Volume :

285

Issue :

Pages :

446-454

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 08 January 2019

Statistics

Number of views

44 (3 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019–32.
Zeichner SB, Arellano ML. Secondary adult acute myeloid leukemia: a review of our evolving understanding of a complex disease process. Curr Treat Options Oncol 2015; 16: 37.
Stolzel F, Pfirrmann M, Aulitzky WE et al. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia 2011; 25: 420–8.
Ramadan SM, Suciu S, Stevens-Kroef M et al. Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON Leukemia Group Trials. Blood 2013; 122: 1.
Selleslag D, Suciu S, Meloni G et al. Low dose clofarabine in combination with a standard remission induction in patients 18–60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A Trial. Haematologica 2017; 102: e47–51.
Amadori S, Suciu S, Selleslag D et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 2016; 34: 972–9.
Hulegardh E, Nilsson C, Lazarevic V et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol 2015; 90: 208–14.
Granfeldt Ostgard LS, Medeiros BC, Sengelov H et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 2015; 33: 3641–9.
Rampal R, Ahn J, Abdel-Wahab O et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014; 111: E5401–10.
Takahashi K, Wang F, Kantarjian H et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 2017; 18: 100–11.
Kayser S, Dohner K, Krauter J et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137–45.
Sengsayadeth S, Labopin M, Boumendil A et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European society for blood and bone marrow transplantation study. Biol Blood Marrow Transplant 2018; 24: 1406–14.
Weisdorf D, Eapen M, Ruggeri A et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant 2014; 20: 816–22.
Ruggeri A, Sanz G, Bittencourt H et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 2014; 28: 779–86.
Eapen M, Rocha V, Sanz G et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653–60.
Baron F, Labopin M, Ruggeri A et al. Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI based regimen. Clin Cancer Res 2018; 24: 2794–803.
Ustun C, Giannotti F, Zhang MJ et al. Outcomes of UCB transplantation are comparable in FLT3 + AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. Leukemia 2017; 31: 1408–14.
Milano F, Gooley T, Wood B et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med 2016; 375: 944–53.
Ringden O, Labopin M, Ehninger G et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570–7.
Baron F, Labopin M, Niederwieser D et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462–8.
Baron F, Ruggeri A, Beohou E et al. RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget 2016; 7: 43027–38.
Baron F, Ruggeri A, Beohou E et al. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol 2017; 10: 128.
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant 2016; 51: 610–1.
Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–9.
Baron F, Ruggeri A, Labopin M et al. Umbilical cord blood transplantation versus unrelated donor transplantation in adults with relapsed or primary refractory acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the EBMT. Bone Marrow Transplant 2017; 52: S80.
Li Z, Labopin M, Ciceri F et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol 2018; 93: 769–77.
Admiraal R, Lindemans CA, van Kesteren C et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood 2016; 128: 2734–41.
Pascal L, Mohty M, Ruggeri A et al. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transplant 2015; 50: 45–50.
Baron F, Ruggeri A, Beohou E et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukemia: a report from Eurocord and the ALWP of the EBMT. J Intern Med 2018; 283: 178–89.
Wagner JE Jr, Brunstein CG, Boitano AE et al. Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell 2016; 18: 144–55.
Anand S, Thomas S, Hyslop T et al. Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant 2017; 23: 1151–7.
Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Expert Rev Hematol 2016; 9: 1–18.
Sengsayadeth S, Gatwood KS, Boumendil A et al. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv 2018; 2: 2127–35.
Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol 2017; 10: 93.
Ehx G, Fransolet G, de Leval L et al. Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology 2017; 6: e1314425.
Fransolet G, Ehx G, Somja J et al. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. J Hematol Oncol 2016; 9: 53.
Shouval R, Ruggeri A, Labopin M et al. An integrative scoring system for survival prediction following umbilical cord blood transplantation in acute leukemia. Clin Cancer Res 2017; 23: 6478–86.
Baron F, Labopin M, Ruggeri A et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol 2015; 8: 107.